Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

Abstract Synthetic oligonucleotides (ODN) that express unmethylated “CpG motifs” trigger cells that express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells. CpG ODN induce an innate immune response characterized by the production of Th1 and pro-inflammatory cyt...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2014-11, Vol.32 (48), p.6377-6389
Main Authors: Scheiermann, Julia, Klinman, Dennis M
Format: Article
Language:English
Subjects:
Adjuvant
Adjuvants, Immunologic - pharmacology
Allergy and Immunology
Applied microbiology
B-Lymphocytes - immunology
Biological and medical sciences
Cancer
Cancer Vaccines - chemistry
Chemokines
Clinical Trials as Topic
CpG olignucleotide
Cytokines - immunology
Dendritic Cells - immunology
Deoxyribonucleic acid
DNA
Fundamental and applied biological sciences. Psychology
Humans
Immune system
Immunity, Innate
Immunology
Infection
Infectious diseases
Ligands
Lymphocytes
Medical sciences
Melanoma
Microbiology
Oligodeoxyribonucleotides - pharmacology
Signal Transduction
Skin cancer
Th1 Cells - immunology
Toll-like receptor
Toll-Like Receptor 9 - immunology
Tumors
Vaccines - chemistry
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Synthetic oligonucleotides (ODN) that express unmethylated “CpG motifs” trigger cells that express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells. CpG ODN induce an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. Their utility as vaccine adjuvants was evaluated in a number of clinical trials. Results indicate that CpG ODN improve antigen presentation and the generation of vaccine-specific cellular and humoral responses. This work provides an up-to-date overview of the utility of CpG ODN as adjuvants for vaccines targeting infectious agents and cancer.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.06.065